Back to Top

"One of today's leaders in investor relations and shareholder services"

Tag Archives: SNWV

SANUWAVE Appoints Daniel M. Jorgensen as Chief Medical Officer

ALPHARETTA, Ga., May 1, 2013 (GLOBE NEWSWIRE) — SANUWAVE Health, Inc. (OTCBB:SNWV) today announced the Company has appointed Daniel M. Jorgensen, MD, MPH, MBA as its Chief Medical Officer. Dr. Jorgensen is an accomplished physician executive with more than 15 years of experience in both earlier stage biotech companies and large pharmaceutical companies, including Pfizer. As Chief Medical Officer, Dr. Jorgensen will oversee the Company’s clinical programs, including the upcoming supplemental clinical trial utilizing dermaPACE┬« for the treatment of diabetic foot ulcers.

Continue Reading

Posted in Client News| Tagged |

A New Audio Interview With Joseph Chiarelli, Chief Executive Officer of SANUWAVE Health, Inc., is Now at SmallCapVoice.com

AUSTIN, Texas, April 23, 2013 (GLOBE NEWSWIRE) — SmallCapVoice.com, Inc. announced today that a new audio interview with SANUWAVE Health, Inc. (SNWV) is now available. The interview can be heard at http://smallcapvoice.com/blog/4-9-13-smallcapvoice-interview-with-sanuwave-health-inc-snwv

Continue Reading

Posted in Client News| Tagged |

4-9-13 SmallCapVoice Interview with SANUWAVE Health, Inc (SNWV)

SNWV

Joseph Chiarelli, Chief Executive Officer of SANUWAVE Health Inc. called into SmallCapVoice.com to go over the business model, market, goals for the company and exciting recent news.

SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of noninvasive, biological response activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. SANUWAVE intends to apply its PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE(R), is CE Marked and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand.

In the U.S., dermaPACE is currently under …

Continue Reading

Posted in Interviews| Tagged |

SANUWAVE Receives U.S. Patent to Sterilize Blood Using Its Shock Wave Technology

ALPHARETTA, Ga., April 11, 2013 (GLOBE NEWSWIRE) — SANUWAVE Health, Inc. (OTCBB:SNWV) has received a patent issued by the U.S. Patent and Trademark Office entitled “Method and Devices for Cleaning and Sterilization with Shock Waves.” The claims of the patent (patent number 8,343,420) relate to a new method that sterilizes blood by applying external shock waves to destroy blood pathogens contained in bags, pipes and tubes. The patent has a term extending to July 2031.

Continue Reading

Posted in Client News| Tagged |